Low-dose melphalan for treatment of high-risk myelodysplastic syndromes.

  title={Low-dose melphalan for treatment of high-risk myelodysplastic syndromes.},
  author={Eijiro Omoto and Seigo Deguchi and Seiji Takaba and Kensuke Kojima and Tomofumi Yano and Yuta Katayama and Kazutaka Sunami and M Takeuchi and Fumihiko Kimura and M. D. N. Harada and Ikurou Kimura},
  volume={10 4},
Twenty-one consecutive patients with high-risk myelodysplastic syndromes (MDS) including six with refractory anemia with excess blasts (RAEB) and 15 with RAEB in transformation (RAEBt) were treated with daily oral low-dose melphalan (2 mg/day). Seven patients achieved complete remission (CR), one patient partial response, and four minor response while the remaining eight did not respond. The median age of the patients was 65 (range 56-83 years). The mean total amount of melphalan given was 140… CONTINUE READING
18 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…